Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 6851 - 6875 of 8179 in total
MK-8666 is under investigation in clinical trial NCT01971554 (Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)).
Investigational
Matched Description: … investigation in clinical trial NCT01971554 (Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of
Nimacimab is under investigation in clinical trial NCT03261739 (Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)).
Investigational
Matched Description: … Nimacimab is under investigation in clinical trial NCT03261739 (Safety Tolerability, and PK of RYI-018 …
Bamocaftor (VX-659) is under investigation in clinical trial NCT03224351 (A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis).
Investigational
Matched Description: … 659) is under investigation in clinical trial NCT03224351 (A Study Evaluating the Safety and Efficacy of
GDC-0084 is under investigation in clinical trial NCT03696355 (Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas).
Investigational
Matched Description: … GDC-0084 is under investigation in clinical trial NCT03696355 (Study of GDC-0084 in Pediatric Patients …
Hypothiocyanite ion is under investigation in clinical trial NCT02598999 (Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients).
Investigational
Matched Description: … Hypothiocyanite ion is under investigation in clinical trial NCT02598999 (Dose Escalation Study of ALX …
Trelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus").
Investigational
Matched Description: … Trelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin …
AZD-1386 is under investigation in clinical trial NCT00945178 (Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers).
Investigational
Matched Description: … NCT00945178 (Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of
Sofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer).
Investigational
Matched Description: … Sofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of
Zetomipzomib is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis).
Investigational
Matched Description: … Zetomipzomib is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate …
Crovalimab is under investigation in clinical trial NCT03157635 (Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria).
Investigational
Matched Description: … clinical trial NCT03157635 (Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of
Giroctocogene fitelparvovec is under investigation in clinical trial NCT04370054 (Study to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia a Adults).
Investigational
Matched Description: … fitelparvovec is under investigation in clinical trial NCT04370054 (Study to Evaluate the Efficacy and Safety of
Revusiran is under investigation in clinical trial NCT02319005 (ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)).
Investigational
Matched Description: … Revusiran is under investigation in clinical trial NCT02319005 (ENDEAVOUR: Phase 3 Multicenter Study of
siG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer).
Investigational
Matched Description: … siG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in …
Talditercept alfa is under investigation in clinical trial NCT03039686 (Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy).
Investigational
Matched Description: … investigation in clinical trial NCT03039686 (Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of
ICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.
Investigational
Matched Description: … It was investigated for the treatment of acute myeloid leukemia. …
LuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.
Investigational
Matched Description: … LuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. …
RP-L102 is a lentiviral vector carrying the Fanconi Anemia-A (FANCA) gene currently being developed by Rocket Pharmaceuticals for the treatment of Fanconi anemia type A
Investigational
Matched Description: … Fanconi Anemia-A (FANCA) gene currently being developed by Rocket Pharmaceuticals for the treatment of
ENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.
Investigational
Matched Description: … Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy …
IMMU-114 is antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific for alpha-chain linked to SN-38 via a CL2A linker.
Investigational
Matched Description: … IMMU-114 is antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific …
XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. The proteins that XL820 inhibit include platelet-derived growth factor receptor beta (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a variety of...
Investigational
Matched Description: … XL820 exhibits dose-dependent growth inhibition in models of breast carcinoma, gliomas and leukemia. ... platelet-derived growth factor receptor alpha, clinically validated targets implicated in a variety of
AMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin. T131...
Investigational
Matched Description: … T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor ... T131 is not structurally related to the thiazolidinedione class of PPARg agonists, which includes Actos …
Lactobacillus plantarum is a member of Lactobacillus, or lactic acid bacteria, that it is widely used in the food industry as a microbial starter and probiotic microorganism. It is considered to be one of versatile species that carry out fermentative and metabolic processes, while exhibiting an antagonistic activity against pathogenic...
Investigational
Matched Description: … *Lactobacillus plantarum* is a member of Lactobacillus, or lactic acid bacteria, that it is widely used ... It is considered to be one of versatile species that carry out fermentative and metabolic processes, …
H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine . It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting . H3B-8800 was granted orphan drug status by the FDA in August 2017 and...
Investigational
Matched Description: … It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome ... was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of
SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID-19. This vaccine candidate resembles the native trimeric viral spike and is produced through mammalian cell-culture. The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. As of June 2020, the company is pursuing a...
Investigational
Matched Description: … ) to test the safety and immunogenicity of the vaccine. ... As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908 …
Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein . It is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults...
Investigational
Matched Description: … 1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of ... It is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide …
Displaying drugs 6851 - 6875 of 8179 in total